EMULSOL Trademark

Trademark Overview

On Wednesday, June 11, 2014, a trademark application was filed for EMULSOL with the United States Patent and Trademark Office. The USPTO has given the EMULSOL trademark a serial number of 86306205. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Thursday, February 11, 2021. This trademark is owned by Ascendia Pharmaceuticals LLC. The EMULSOL trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical drug development services, namely, production of oil-in-water nanoemulsions
emulsol

General Information

Serial Number86306205
Word MarkEMULSOL
Filing DateWednesday, June 11, 2014
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateThursday, February 11, 2021
Registration Number4842223
Registration DateTuesday, October 27, 2015
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 14, 2015

Trademark Statements

Goods and ServicesPharmaceutical drug development services, namely, production of oil-in-water nanoemulsions

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, June 20, 2014
Primary Code042
First Use Anywhere DateSunday, November 2, 2014
First Use In Commerce DateThursday, April 30, 2015

Trademark Owner History

Party NameAscendia Pharmaceuticals LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressNorth Brunswick, NJ 08902
Party NameAscendia Pharmaceuticals LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressNorth Brunswick, NJ 08902
Party NameAscendia Pharmaceuticals LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNorth Brunswick, NJ 08902

Trademark Events

Event DateEvent Description
Saturday, June 14, 2014NEW APPLICATION ENTERED
Friday, June 20, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 22, 2014ASSIGNED TO EXAMINER
Thursday, September 25, 2014NON-FINAL ACTION WRITTEN
Thursday, September 25, 2014NON-FINAL ACTION E-MAILED
Thursday, September 25, 2014NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 2, 2015ASSIGNED TO LIE
Monday, March 2, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 2, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 2, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 14, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 15, 2015USE AMENDMENT FILED
Monday, February 23, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, February 23, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 10, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, March 25, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 14, 2015PUBLISHED FOR OPPOSITION
Tuesday, June 9, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 15, 2015TEAS STATEMENT OF USE RECEIVED
Wednesday, September 23, 2015STATEMENT OF USE PROCESSING COMPLETE
Wednesday, September 23, 2015ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, September 24, 2015NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, October 27, 2015REGISTERED-PRINCIPAL REGISTER
Tuesday, October 27, 2020TEAS SECTION 8 & 15 RECEIVED
Tuesday, October 27, 2020COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, September 22, 2015CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 5, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, February 11, 2021REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Thursday, February 11, 2021NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Monday, October 28, 2024COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

Related Keywords

emulsol production water nanoemulsions namely services drug development pharmaceutical